Neuroprotective Products Market Global Overview: 2023-2029


Neuroprotective Products Market is expected to reach US$ 5.03 Mn. at a CAGR of 7% during the forecast period 2029.

Neuroprotective products provide medications that is used to protect or preserve the nerve cells of the brain and central nervous system. The neuroprotective products are effective especially in case of degeneration, stress, and injury.

The report on the Neuroprotective Products Market gives an estimation of the development of the market based on historical studies and also provides forecasts based on a comprehensive research. The report gives a complete market analysis for the forecast period from 2023 to 2029.

Neuroprotective Products MarketTo know about the Research Methodology :- Request Free Sample Report

The market is divided into various segments with an in-depth outlook of the competitors and a listing of the profiled key players. Some of the major key players in the global market includes BHR Pharma LLC, NeuroVive Pharmaceutical AB, Neuren Pharmaceuticals Limited, Genervon Biopharmaceuticals LLC, Varinel Inc. The market size in terms of revenue and volume is calculated and provided for the study period along with the dynamics of the market such as the drivers and the restraints.

Neuroprotective Products Market Dynamics

Neurodegenerative diseases and their rapidly increasing prevalence drives the neuroprotective products market during forecast period for their treatment and care. The demand for neuroprotectives in the future creates the opportunity for the global market. Growing geriatric population and growing need of this life protective products commanded the global market growth in the forecast period. Growing research and development activities concerning the healthcare sector is the another factor command the largest market growth in the forecast period.

Spinal Cord Injury (SCS) is a dominating segment for the global Neuroprotective Products Market.

The Neuroprotective products are generally used in the treatment of spinal cord injury for its minimally invasive, safe operation as well as reversible modality with limited side effect profile.

The current prevalence of patients with chronic pain requiring treatment other than conventional medical management hence the need for neuroprotective products increased.

Neuroprotective products are the essential products for treatment algorithm for patients suffering from neuropathic pain. Neuroprotective products are the reversible, minimally invasive approach to treat pain that has goals of reducing, suffering, improving function, reducing health care utilization, reducing opioid use, and improving quality of life. Neuroprotective products is an efficacious, cost-effective option that should be used much earlier in the treatment continuum in many disease states, including lumbar and cervical radiculopathy, failed back surgery syndrome, peripheral neuropathy, ischemic pain, and other disorders affecting central nervous system.

Neuroprotective product has shown that, it is the best product to improve blood flow, improve tissue oxygenation, and enhanced wound healing. Hence, it is used in patients who have either severe ischemic pain or mixed pain of both ischemic and neuropathic origin.

Parkinson’s disease held the largest share of the global internal neuromodulation devices market during forecast period 2022-2029.

Neuromodulation devices used to help patients with Parkinson's disease symptoms. People with Parkinson’s who do not respond well to medications, use deep brain stimulator a neuromodulator device, which help in mostly all surgical procedure that stimulate the brain in a way that helps stop many of the movement-related symptoms of Parkinson's, such as tremor, slowness of movement, and rigidity.

Neuromodulation devices include physical, occupational, and speech therapies, which help with gait and voice disorders, tremors and rigidity, and decline in mental functions. The neuromodulation devices also help to strengthen muscles and improve balance. As a result Parkinson’s disease segment is expected to command the largest market share of xx% by 2029.

Neuroprotective Products Market Scope: Inquire before buying






Neuroprotective Products Market




Report Coverage
Details




Base Year:
2022
Forecast Period:
2023-2029




Historical Data:
2017 to 2022
Market Size in 2022:
US $ 3.13 Mn.




Forecast Period 2023 to 2029 CAGR:
7%
Market Size in 2029:
US $ 5.03 Mn.




 Segments Covered:
by End-User
• Alzheimer's disease
• Parkinson's disease
• Spinal Cord Injury
• Stroke
• Brain injury






Neuroprotective Products Market, by Region

• North America (United States, Canada and Mexico)
• Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
• Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
• Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
• South America (Brazil, Argentina Rest of South America)

Increase in the incidence of life-threatening diseases and brain injuries has led to the increasing usage of neuroprotective products, which help to boost the global market worldwide.

Significant advancements in medical management as well as technology with arrivals of newer generation products & devices have improved patient outcomes, which leads to increase use of neuroprotective products in diagnosis and treatment.

Introduction of basic general medical training programme and establishment of dispensaries at sub-division and district level at the hospital, drive hospital segment during forecast period. Availability of health service to all citizens, irrespective of their ability to pay for it, and it should be complete medical service, in which all the facilities required for the treatment and prevention of disease as well as for the promotion of positive health are provided.

Governments across globe have main focus on higher education, research, and national health programmes, for example, family welfare, primary health care and prevention, control, and eradication of major diseases which form the main plank of development efforts in global neuroprotective products market. The Department of Health has made strategic interventions to ensure more vigorous implementation and to improve the effectiveness of different global health products aimed at combating communicable and non-communicable diseases. Global government hospitals to raise the quality of their services, introduce transparency and accountability, and to provide products with courtesy and efficiency to the patient. Hence, this all factors are expected to command largest market share of xx% from 2022 to 2029.

Europe is expected to command the largest global Neuroprotective Products market share of xx% with USD xx Mn growth in the forecast period of 2022 to 2029.

Public and private organizations from Europe are taking initiatives to increase awareness of growing neurological disorders and the growth of the mental health market.

The use of neuroprotective products with recent technological innovations drive the global market from Europe. Rise in the number of patients with neurological disorders and problems occurring due to accidents, trauma, hypertension and hectic lifestyle is anticipated to drive the global neuroprotective products market in this region. Preference for minimally invasive procedures by doctors & professionals is helps to grow global market from Europe.

Key Players Operating in the Neuroprotective Products Market

● BHR Pharma LLC
● NeuroVive Pharmaceutical AB
● Neuren Pharmaceuticals Limited
● Genervon Biopharmaceuticals LLC
● Varinel Inc.
● Allon Therapeutics Inc.
● Bionure
● Ceregene
● Allon therapeutics
● Neuren Pharmaceuticals

Frequently Asked Questions:

1. Which region has the largest share in Global Neuroprotective Products Market?
Ans: Europe region held the highest share in 2022.

2. What is the growth rate of Global Neuroprotective Products Market?
Ans: The Global Neuroprotective Products Market is growing at a CAGR of 7% during forecasting period 2023-2029.

3. What is scope of the Global Neuroprotective Products Market report?
Ans: Global Neuroprotective Products Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period.

4. Who are the key players in Global Neuroprotective Products Market?
Ans: The important key players in the Global Neuroprotective Products Market are – BHR Pharma LLC,NeuroVive Pharmaceutical AB,Neuren Pharmaceuticals Limited,Genervon Biopharmaceuticals LLC,Varinel Inc.,Allon Therapeutics Inc.,Bionure,Ceregene,Allon therapeutics,Neuren Pharmaceuticals

5. What is the study period of this Market?
Ans: The Global Neuroprotective Products Market is studied from 2022 to 2029. 




Global Neuroprotective Products Market

1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
1.3. Research Objectives

2. Assumptions and Research Methodology
2.1. Report Assumptions
2.2. Abbreviations
2.3. Research Methodology
2.3.1. Secondary Research
2.3.1.1. Secondary data
2.3.1.2. Secondary Sources
2.3.2. Primary Research
2.3.2.1. Data from Primary Sources
2.3.2.2. Breakdown of Primary Sources

3. Executive Summary: Neuroprotective Products Market Size, by Market Value (US$ Mn)

4. Market Overview
4.1. Introduction
4.2. Market Indicator
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.2.4. Challenges
4.3. Porter’s Analysis
4.4. Value Chain Analysis
4.5. Market Risk Analysis
4.6. SWOT Analysis
4.7. Industry Trends and Emerging Technologies

5. Supply Side and Demand Side Indicators

6. Global Neuroprotective Products Market Analysis and Forecast
6.1. Neuroprotective Products Market Size & Y-o-Y Growth Analysis
6.1.1. North America
6.1.2. Europe
6.1.3. Asia Pacific
6.1.4. Middle East & Africa
6.1.5. South America

7. Global Neuroprotective Products Market Analysis and Forecast, by Medical Condition
7.1. Introduction and Definition
7.2. Key Findings
7.3. Neuroprotective Products Market Value Share Analysis, by Medical Condition
7.4. Neuroprotective Products Market Size (US$ Mn) Forecast, by Medical Condition
7.5. Neuroprotective Products Market Analysis, by Medical Condition
7.6. Neuroprotective Products Market Attractiveness Analysis, by Medical Condition

8. Global Neuroprotective Products Market Analysis and Forecast, by End User
8.1. Introduction and Definition
8.2. Key Findings
8.3. Neuroprotective Products Market Value Share Analysis, by End User
8.4. Neuroprotective Products Market Size (US$ Mn) Forecast, by End User
8.5. Neuroprotective Products Market Analysis, by End User
8.6. Neuroprotective Products Market Attractiveness Analysis, by End User

9. Global Neuroprotective Products Market Analysis, by Region
9.1. Neuroprotective Products Market Value Share Analysis, by Region
9.2. Neuroprotective Products Market Size (US$ Mn) Forecast, by Region
9.3. Neuroprotective Products Market Attractiveness Analysis, by Region

10. North America Neuroprotective Products Market Analysis
10.1. Key Findings
10.2. North America Neuroprotective Products Market Overview
10.3. North America Neuroprotective Products Market Value Share Analysis, by Medical Condition
10.4. North America Neuroprotective Products Market Forecast, by Medical Condition
10.4.1. Alzheimer's disease
10.4.2. Parkinson's disease
10.4.3. Spinal Cord Injury
10.4.4. Stroke
10.4.5. Other Brain injury
10.5. North America Neuroprotective Products Market Value Share Analysis, by End User
10.6. North America Neuroprotective Products Market Forecast, by End User
10.6.1. Hospitals
10.6.2. Clinics
10.6.3. Others
10.7. North America Neuroprotective Products Market Value Share Analysis, by Country
10.8. North America Neuroprotective Products Market Forecast, by Country
10.8.1. U.S.
10.8.2. Canada
10.8.3. Mexico
10.9. North America Neuroprotective Products Market Analysis, by Country
10.10. U.S. Neuroprotective Products Market Forecast, by Medical Condition
10.10.1. Alzheimer's disease
10.10.2. Parkinson's disease
10.10.3. Spinal Cord Injury
10.10.4. Stroke
10.10.5. Other Brain injury
10.11. U.S. Neuroprotective Products Market Forecast, by End User
10.11.1. Hospitals
10.11.2. Clinics
10.11.3. Others
10.12. Canada Neuroprotective Products Market Forecast, by Medical Condition
10.12.1. Alzheimer's disease
10.12.2. Parkinson's disease
10.12.3. Spinal Cord Injury
10.12.4. Stroke
10.12.5. Other Brain injury
10.13. Canada Neuroprotective Products Market Forecast, by End User
10.13.1. Hospitals
10.13.2. Clinics
10.13.3. Others
10.14. Mexico Neuroprotective Products Market Forecast, by Medical Condition
10.14.1. Alzheimer's disease
10.14.2. Parkinson's disease
10.14.3. Spinal Cord Injury
10.14.4. Stroke
10.14.5. Other Brain injury
10.15. Mexico Neuroprotective Products Market Forecast, by End User
10.15.1. Hospitals
10.15.2. Clinics
10.15.3. Others
10.16. North America Neuroprotective Products Market Attractiveness Analysis
10.16.1. by Medical Condition
10.16.2. by End User
10.17. PEST Analysis
10.18. Key Trends
10.19. Key Developments

11. Europe Neuroprotective Products Market Analysis
11.1. Key Findings
11.2. Europe Neuroprotective Products Market Overview
11.3. Europe Neuroprotective Products Market Value Share Analysis, by Medical Condition
11.4. Europe Neuroprotective Products Market Forecast, by Medical Condition
11.4.1. Alzheimer's disease
11.4.2. Parkinson's disease
11.4.3. Spinal Cord Injury
11.4.4. Stroke
11.4.5. Other Brain injury
11.5. Europe Neuroprotective Products Market Value Share Analysis, by End User
11.6. Europe Neuroprotective Products Market Forecast, by End User
11.6.1. Hospitals
11.6.2. Clinics
11.6.3. Others
11.7. Europe Neuroprotective Products Market Value Share Analysis, by Country
11.8. Europe Neuroprotective Products Market Forecast, by Country
11.8.1. Germany
11.8.2. U.K.
11.8.3. France
11.8.4. Italy
11.8.5. Spain
11.8.6. Sweden
11.8.7. CIS countries
11.8.8. Rest of Europe
11.9. Germany Neuroprotective Products Market Forecast, by Medical Condition
11.9.1. Alzheimer's disease
11.9.2. Parkinson's disease
11.9.3. Spinal Cord Injury
11.9.4. Stroke
11.9.5. Other Brain injury
11.10. Germany Neuroprotective Products Market Forecast, by End User
11.10.1. Hospitals
11.10.2. Clinics
11.10.3. Others
11.11. U.K. Neuroprotective Products Market Forecast, by Medical Condition
11.11.1. Alzheimer's disease
11.11.2. Parkinson's disease
11.11.3. Spinal Cord Injury
11.11.4. Stroke
11.11.5. Other Brain injury
11.12. U.K. Neuroprotective Products Market Forecast, by End User
11.12.1. Hospitals
11.12.2. Clinics
11.12.3. Others
11.13. France Neuroprotective Products Market Forecast, by Medical Condition
11.13.1. Alzheimer's disease
11.13.2. Parkinson's disease
11.13.3. Spinal Cord Injury
11.13.4. Stroke
11.13.5. Other Brain injury
11.14. France Neuroprotective Products Market Forecast, by End User
11.14.1. Hospitals
11.14.2. Clinics
11.14.3. Others
11.15. Italy Neuroprotective Products Market Forecast, by Medical Condition
11.15.1. Alzheimer's disease
11.15.2. Parkinson's disease
11.15.3. Spinal Cord Injury
11.15.4. Stroke
11.15.5. Other Brain injury
11.16. Italy Neuroprotective Products Market Forecast, by End User
11.16.1. Hospitals
11.16.2. Clinics
11.16.3. Others
11.17. Spain Neuroprotective Products Market Forecast, by Medical Condition
11.17.1. Alzheimer's disease
11.17.2. Parkinson's disease
11.17.3. Spinal Cord Injury
11.17.4. Stroke
11.17.5. Other Brain injury
11.18. Spain Neuroprotective Products Market Forecast, by End User
11.18.1. Hospitals
11.18.2. Clinics
11.18.3. Others
11.19. Sweden Neuroprotective Products Market Forecast, by Medical Condition
11.19.1. Alzheimer's disease
11.19.2. Parkinson's disease
11.19.3. Spinal Cord Injury
11.19.4. Stroke
11.19.5. Other Brain injury
11.20. Sweden Neuroprotective Products Market Forecast, by End User
11.20.1. Hospitals
11.20.2. Clinics
11.20.3. Others
11.21. CIS countries Neuroprotective Products Market Forecast, by Medical Condition
11.21.1. Alzheimer's disease
11.21.2. Parkinson's disease
11.21.3. Spinal Cord Injury
11.21.4. Stroke
11.21.5. Other Brain injury
11.22. CIS countries Neuroprotective Products Market Forecast, by End User
11.22.1. Hospitals
11.22.2. Clinics
11.22.3. Others
11.23. Rest of Europe Neuroprotective Products Market Forecast, by Medical Condition
11.23.1. Alzheimer's disease
11.23.2. Parkinson's disease
11.23.3. Spinal Cord Injury
11.23.4. Stroke
11.23.5. Other Brain injury
11.24. Rest of Europe Neuroprotective Products Market Forecast, by End User
11.24.1. Hospitals
11.24.2. Clinics
11.24.3. Others
11.25. Europe Neuroprotective Products Market Attractiveness Analysis
11.25.1. by End User
11.25.2. by Medical Condition
11.26. PEST Analysis
11.27. Key Trends
11.28. Key Developments

12. Asia Pacific Neuroprotective Products Market Analysis
12.1. Key Findings
12.2. Asia Pacific Neuroprotective Products Market Overview
12.3. Asia Pacific Neuroprotective Products Market Value Share Analysis, by Medical Condition
12.4. Asia Pacific Neuroprotective Products Market Forecast, by Medical Condition
12.4.1. Alzheimer's disease
12.4.2. Parkinson's disease
12.4.3. Spinal Cord Injury
12.4.4. Stroke
12.4.5. Other Brain injury
12.5. Asia Pacific Neuroprotective Products Market Value Share Analysis, by End User
12.6. Asia Pacific Neuroprotective Products Market Forecast, by End User
12.6.1. Hospitals
12.6.2. Clinics
12.6.3. Others
12.7. Asia Pacific Neuroprotective Products Market Value Share Analysis, by Country
12.8. Asia Pacific Neuroprotective Products Market Forecast, by Country
12.8.1. China
12.8.2. India
12.8.3. Japan
12.8.4. South Korea
12.8.5. Australia
12.8.6. ASEAN
12.8.7. Rest of Asia Pacific
12.9. Asia Pacific Neuroprotective Products Market Analysis, by Country
12.10. China Neuroprotective Products Market Forecast, by Medical Condition
12.10.1. Alzheimer's disease
12.10.2. Parkinson's disease
12.10.3. Spinal Cord Injury
12.10.4. Stroke
12.10.5. Other Brain injury
12.11. China Neuroprotective Products Market Forecast, by End User
12.11.1. Hospitals
12.11.2. Clinics
12.11.3. Others
12.12. India Neuroprotective Products Market Forecast, by Medical Condition
12.12.1. Alzheimer's disease
12.12.2. Parkinson's disease
12.12.3. Spinal Cord Injury
12.12.4. Stroke
12.12.5. Other Brain injury
12.13. India Neuroprotective Products Market Forecast, by End User
12.13.1. Hospitals
12.13.2. Clinics
12.13.3. Others
12.14. Japan Neuroprotective Products Market Forecast, by Medical Condition
12.14.1. Alzheimer's disease
12.14.2. Parkinson's disease
12.14.3. Spinal Cord Injury
12.14.4. Stroke
12.14.5. Other Brain injury
12.15. Japan Neuroprotective Products Market Forecast, by End User
12.15.1. Hospitals
12.15.2. Clinics
12.15.3. Others
12.16. South Korea Neuroprotective Products Market Forecast, by Medical Condition
12.16.1. Alzheimer's disease
12.16.2. Parkinson's disease
12.16.3. Spinal Cord Injury
12.16.4. Stroke
12.16.5. Other Brain injury
12.17. South Korea Neuroprotective Products Market Forecast, by End User
12.17.1. Hospitals
12.17.2. Clinics
12.17.3. Others
12.18. Australia Neuroprotective Products Market Forecast, by Medical Condition
12.18.1. Alzheimer's disease
12.18.2. Parkinson's disease
12.18.3. Spinal Cord Injury
12.18.4. Stroke
12.18.5. Other Brain injury
12.19. Australia Neuroprotective Products Market Forecast, by End User
12.19.1. Hospitals
12.19.2. Clinics
12.19.3. Others
12.20. ASEAN Neuroprotective Products Market Forecast, by Medical Condition
12.20.1. Alzheimer's disease
12.20.2. Parkinson's disease
12.20.3. Spinal Cord Injury
12.20.4. Stroke
12.20.5. Other Brain injury
12.21. ASEAN Neuroprotective Products Market Forecast, by End User
12.21.1. Hospitals
12.21.2. Clinics
12.21.3. Others
12.22. Rest of Asia Pacific Neuroprotective Products Market Forecast, by Medical Condition
12.22.1. Alzheimer's disease
12.22.2. Parkinson's disease
12.22.3. Spinal Cord Injury
12.22.4. Stroke
12.22.5. Other Brain injury
12.23. Rest of Asia Pacific Neuroprotective Products Market Forecast, by End User
12.23.1. Hospitals
12.23.2. Clinics
12.23.3. Others
12.24. Asia Pacific Neuroprotective Products Market Attractiveness Analysis
12.24.1. by Medical Condition
12.24.2. by End User
12.25. PEST Analysis
12.26. Key Trends
12.27. Key Developments

13. Middle East & Africa Neuroprotective Products Market Analysis
13.1. Key Findings
13.2. Middle East & Africa Neuroprotective Products Market Overview
13.3. Middle East & Africa Neuroprotective Products Market Value Share Analysis, by Medical Condition
13.4. Middle East & Africa Neuroprotective Products Market Forecast, by Medical Condition
13.4.1. Alzheimer's disease
13.4.2. Parkinson's disease
13.4.3. Spinal Cord Injury
13.4.4. Stroke
13.4.5. Other Brain injury
13.5. Middle East & Africa Neuroprotective Products Market Value Share Analysis, by End User
13.6. Middle East & Africa Neuroprotective Products Market Forecast, by End User
13.6.1. Hospitals
13.6.2. Clinics
13.6.3. Others
13.7. Middle East & Africa Neuroprotective Products Market Value Share Analysis, by Country
13.8. Middle East & Africa Neuroprotective Products Market Forecast, by Country
13.8.1. GCC Countries
13.8.2. South Africa
13.8.3. Nigeria
13.8.4. Egypt
13.8.5. Rest of Middle East & Africa
13.9. Middle East & Africa Neuroprotective Products Market Analysis, by Country
13.10. GCC Countries Neuroprotective Products Market Forecast, by Medical Condition
13.10.1. Alzheimer's disease
13.10.2. Parkinson's disease
13.10.3. Spinal Cord Injury
13.10.4. Stroke
13.10.5. Other Brain injury
13.11. GCC Countries Neuroprotective Products Market Forecast, by End User
13.11.1. Hospitals
13.11.2. Clinics
13.11.3. Others
13.12. South Africa Neuroprotective Products Market Forecast, by Medical Condition
13.12.1. Alzheimer's disease
13.12.2. Parkinson's disease
13.12.3. Spinal Cord Injury
13.12.4. Stroke
13.12.5. Other Brain injury
13.13. South Africa Neuroprotective Products Market Forecast, by End User
13.13.1. Hospitals
13.13.2. Clinics
13.13.3. Others
13.14. Nigeria Neuroprotective Products Market Forecast, by Medical Condition
13.14.1. Alzheimer's disease
13.14.2. Parkinson's disease
13.14.3. Spinal Cord Injury
13.14.4. Stroke
13.14.5. Other Brain injury
13.15. Nigeria Neuroprotective Products Market Forecast, by End User
13.15.1. Hospitals
13.15.2. Clinics
13.15.3. Others
13.16. Egypt Neuroprotective Products Market Forecast, by Medical Condition
13.16.1. Alzheimer's disease
13.16.2. Parkinson's disease
13.16.3. Spinal Cord Injury
13.16.4. Stroke
13.16.5. Other Brain injury
13.17. Egypt Neuroprotective Products Market Forecast, by End User
13.17.1. Hospitals
13.17.2. Clinics
13.17.3. Others
13.18. Rest of Middle East & Africa Neuroprotective Products Market Forecast, by Medical Condition
13.18.1. Alzheimer's disease
13.18.2. Parkinson's disease
13.18.3. Spinal Cord Injury
13.18.4. Stroke
13.18.5. Other Brain injury
13.19. Rest of Middle East & Africa Neuroprotective Products Market Forecast, by End User
13.19.1. Hospitals
13.19.2. Clinics
13.19.3. Others
13.20. Middle East & Africa Neuroprotective Products Market Attractiveness Analysis
13.20.1. by Medical Condition
13.20.2. by End User
13.21. PEST Analysis
13.22. Key Trends
13.23. Key Developments

14. South America Neuroprotective Products Market Analysis
14.1. Key Findings
14.2. South America Neuroprotective Products Market Overview
14.3. South America Neuroprotective Products Market Value Share Analysis, by Medical Condition
14.4. South America Neuroprotective Products Market Forecast, by Medical Condition
14.4.1. Alzheimer's disease
14.4.2. Parkinson's disease
14.4.3. Spinal Cord Injury
14.4.4. Stroke
14.4.5. Other Brain injury
14.5. South America Neuroprotective Products Market Value Share Analysis, by End User
14.6. South America Neuroprotective Products Market Forecast, by End User
14.6.1. Hospitals
14.6.2. Clinics
14.6.3. Others
14.7. South America Neuroprotective Products Market Value Share Analysis, by Country
14.8. South America Neuroprotective Products Market Forecast, by Country
14.8.1. Brazil
14.8.2. Colombia
14.8.3. Argentina
14.8.4. Rest of South America
14.9. South America Neuroprotective Products Market Analysis, by Country
14.10. Brazil Neuroprotective Products Market Forecast, by Medical Condition
14.10.1. Alzheimer's disease
14.10.2. Parkinson's disease
14.10.3. Spinal Cord Injury
14.10.4. Stroke
14.10.5. Other Brain injury
14.11. Brazil Neuroprotective Products Market Forecast, by End User
14.11.1. Hospitals
14.11.2. Clinics
14.11.3. Others
14.12. Colombia Neuroprotective Products Market Forecast, by Medical Condition
14.12.1. Alzheimer's disease
14.12.2. Parkinson's disease
14.12.3. Spinal Cord Injury
14.12.4. Stroke
14.12.5. Other Brain injury
14.13. Colombia Neuroprotective Products Market Forecast, by End User
14.13.1. Hospitals
14.13.2. Clinics
14.13.3. Others
14.14. Argentina Neuroprotective Products Market Forecast, by Medical Condition
14.14.1. Alzheimer's disease
14.14.2. Parkinson's disease
14.14.3. Spinal Cord Injury
14.14.4. Stroke
14.14.5. Other Brain injury
14.15. Argentina Neuroprotective Products Market Forecast, by End User
14.15.1. Hospitals
14.15.2. Clinics
14.15.3. Others
14.16. Rest of South America Neuroprotective Products Market Forecast, by Medical Condition
14.16.1. Alzheimer's disease
14.16.2. Parkinson's disease
14.16.3. Spinal Cord Injury
14.16.4. Stroke
14.16.5. Other Brain injury
14.17. Rest of South America Neuroprotective Products Market Forecast, by End User
14.17.1. Hospitals
14.17.2. Clinics
14.17.3. Others
14.18. South America Neuroprotective Products Market Attractiveness Analysis
14.18.1. by Medical Condition
14.18.2. by End User
14.19. PEST Analysis
14.20. Key Trends
14.21. Key Developments

15. Company Profiles
15.1. Market Share Analysis, by Company
15.2. Competition Matrix

15.2.1. Competitive Benchmarking of key players by price, presence, market share, Component, and R&D investment
15.2.2. New Product Launches and Product Enhancements
15.2.3. Market Consolidation
15.2.3.1. M&A by Regions, Investment and Component
15.2.3.2. M&A Key Players, Forward Integration and Backward Integration

15.3. Company Profiles: Key Players
15.3.1. BHR Pharma LLC
15.3.1.1. Company Overview
15.3.1.2. Financial Overview
15.3.1.3. Product Portfolio
15.3.1.4. Business Strategy
15.3.1.5. Recent Developments
15.3.1.6. Development Footprint
15.3.2. NeuroVive Pharmaceutical AB
15.3.3. Neuren Pharmaceuticals Limited
15.3.4. Genervon Biopharmaceuticals LLC
15.3.5. Varinel Inc.
15.3.6. Allon Therapeutics Inc.
15.3.7. Bionure
15.3.8. Ceregene
15.3.9. Allon therapeutics
15.3.10. Neuren Pharmaceuticals

16. Primary key Insights
  • INQUIRE BEFORE BUYING